Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Actinogen Medical ( (AU:ACW) ) is now available.
Actinogen Medical has announced a proposed issue of up to 119,047,619 new ordinary fully paid shares under a securities purchase plan, with a record date of 30 January 2026, an offer closing date of 24 February 2026, and an issue date of 2 March 2026. The capital raising via the share purchase plan is intended to broaden shareholder participation and strengthen the company’s balance sheet, which may support ongoing clinical development activities and enhance its financial flexibility in the competitive biotech sector.
The most recent analyst rating on (AU:ACW) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.
More about Actinogen Medical
Actinogen Medical Limited (ASX: ACW) is an Australian-listed biotechnology company operating in the medical and life sciences sector, focused on developing pharmaceutical and therapeutic products. The company’s activities centre on clinical-stage drug development, with its ordinary fully paid shares traded on the ASX under the ticker ACW.
YTD Price Performance: -26.23%
Average Trading Volume: 5,840,451
Technical Sentiment Signal: Hold
Current Market Cap: A$143.6M
Find detailed analytics on ACW stock on TipRanks’ Stock Analysis page.